Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In this international, multicenter trial, we randomly assigned 400 patients with severe symptomatic ...

MONDAY, Nov. 4, 2024 (HealthDay News) -- Transcatheter tricuspid-valve replacement is superior to medical therapy alone for ...

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement ...

A new study published in the New England Journal of Medicine showed that improvements in symptoms and quality of life were ...

A novel study conducted by researchers from New York and Boston identified certain circulating biomarkers that can ...

NEW YORK, NY / ACCESSWIRE / November 23, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to ...

New York, New York-- (Newsfile Corp. - November 23, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation ...

The Transcatheter Mitral and Tricuspid Therapies ... Large, underpenetrated market: The mitral and tricuspid valve repair and replacement markets are substantially underpenetrated compared ...

A Charleston woman was always short of breath and suffered from an undertreated heart problem. A new device at MUSC has her ...

Edwards categorizes its therapies and technologies into four categories: Transcatheter Aortic Valve Replacement ("TAVR"), Transcatheter Mitral and Tricuspid Therapies ("TMTT"), Surgical Structural ...

EW LEGAL DEADLINE: The Edwards Lifesciences Securities Class Action Deadline Is Approaching – Contact BFA Law Now If You Lost Money (NYSE:EW) ...